JP2024535060A5 - - Google Patents

Info

Publication number
JP2024535060A5
JP2024535060A5 JP2024517061A JP2024517061A JP2024535060A5 JP 2024535060 A5 JP2024535060 A5 JP 2024535060A5 JP 2024517061 A JP2024517061 A JP 2024517061A JP 2024517061 A JP2024517061 A JP 2024517061A JP 2024535060 A5 JP2024535060 A5 JP 2024535060A5
Authority
JP
Japan
Prior art keywords
antigen
binding domain
domain according
binding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/075794 external-priority patent/WO2023041717A1/en
Publication of JP2024535060A publication Critical patent/JP2024535060A/ja
Publication of JP2024535060A5 publication Critical patent/JP2024535060A5/ja
Pending legal-status Critical Current

Links

JP2024517061A 2021-09-16 2022-09-16 抗ヒトcd45rc結合ドメインおよびその使用 Pending JP2024535060A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306283.9 2021-09-16
EP21306283 2021-09-16
PCT/EP2022/075794 WO2023041717A1 (en) 2021-09-16 2022-09-16 Anti-human cd45rc binding domains and uses thereof

Publications (2)

Publication Number Publication Date
JP2024535060A JP2024535060A (ja) 2024-09-26
JP2024535060A5 true JP2024535060A5 (enExample) 2025-10-01

Family

ID=78402053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517061A Pending JP2024535060A (ja) 2021-09-16 2022-09-16 抗ヒトcd45rc結合ドメインおよびその使用

Country Status (9)

Country Link
US (1) US20250281535A1 (enExample)
EP (1) EP4401842B1 (enExample)
JP (1) JP2024535060A (enExample)
CN (1) CN118369344A (enExample)
CA (1) CA3231944A1 (enExample)
ES (1) ES3047544T3 (enExample)
FI (1) FI4401842T3 (enExample)
PL (1) PL4401842T3 (enExample)
WO (1) WO2023041717A1 (enExample)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス, インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
JP4658125B2 (ja) 2005-06-28 2011-03-23 パイオニア株式会社 放送受信装置、妨害検出装置および妨害検出方法
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
KR20140133958A (ko) 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
TWI828625B (zh) 引導及導航控制蛋白質以及彼之製造及使用方法
JP6681327B2 (ja) 抗pd−1抗体およびその応用
KR101671039B1 (ko) 항 cxcr4 항체 및 그들의 암의 치료를 위한 용도
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
CN112390892B (zh) 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
JP2022530542A5 (enExample)
JP2022548778A5 (enExample)
JP7796034B2 (ja) ヒトcd45rcに特異的なキメラ抗原受容体およびその使用
JP2022512917A5 (enExample)
JP2023519099A5 (enExample)
JP2022542559A5 (enExample)
JP2021520201A5 (enExample)
JP2023518538A5 (enExample)
JP2024505600A5 (enExample)
JP2024525492A5 (enExample)
WO2007102230A1 (ja) ヒト化抗cd20モノクローナル抗体
JP2023515055A5 (enExample)
WO2022161278A1 (zh) 抗tigit抗体及其应用
JP2024535060A5 (enExample)
RU2805840C1 (ru) Полипептид, специфичный к муцину-1, и его применение
FI4401842T3 (fi) Ihmisen cd45rc:hen sitoutuvia domeeneita ja niiden käyttöjä
HK40097671A (zh) 制导和导航控制蛋白及其制备和使用方法
HK40097672A (zh) 制导和导航控制蛋白及其制备和使用方法
HK40109798A (zh) 制导和导航控制蛋白及其制备和使用方法